These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

92 related items for PubMed ID: 12951976

  • 1. [Graves-Basedow disease, factors that influence in their relapse].
    Martí Cabané J.
    An Med Interna; 2003 Jul; 20(7):388. PubMed ID: 12951976
    [No Abstract] [Full Text] [Related]

  • 2. [Clinical evolution of a cohort of patients with Graves-Basedow disease treated with metimazole].
    De Luis DA, Arconada A, Aller R, Cuéllar LA, Terroba MC, Martín Gil J.
    Med Clin (Barc); 2002 Jun 01; 118(20):777-8. PubMed ID: 12049693
    [Abstract] [Full Text] [Related]

  • 3. [Inorganic and organic phases of radioiodine metabolism in the thyroid in Basedow patients treated with synthetic thyroid antagonists].
    Valentini F, Lodeserto A, Reschini E, Vivarelli S, Miedico D.
    Folia Endocrinol; 1968 Aug 01; 21(4):385-95. PubMed ID: 4186148
    [No Abstract] [Full Text] [Related]

  • 4. [Prognostic factors of relapse in drug therapy of Graves-Basedow disease].
    Jover Díaz F, Sánchez Ruiz B, Pinedo Díaz R, Domínguez Escribano JR.
    Rev Clin Esp; 2002 May 01; 202(5):300-1. PubMed ID: 12060552
    [No Abstract] [Full Text] [Related]

  • 5. Medical aspects on surgery in Graves' disease. Clinical review.
    Karlsson FA, Winsa B, Rastad J, Johansson H.
    Acta Chir Scand; 1990 Jan 01; 156(1):47-51. PubMed ID: 1690941
    [No Abstract] [Full Text] [Related]

  • 6. Binding, stimulating and blocking TSH receptor antibodies to the thyrotropin receptor as predictors of relapse of Graves' disease after withdrawal of antithyroid treatment.
    Quadbeck B, Hoermann R, Hahn S, Roggenbuck U, Mann K, Janssen OE.
    Horm Metab Res; 2005 Dec 01; 37(12):745-50. PubMed ID: 16372228
    [Abstract] [Full Text] [Related]

  • 7. Effect of universal salt iodization on antithyroid drugs.
    Dai WX, Lian XL, Lu L, Li SM, Li SH, Li XW.
    Chin Med J (Engl); 2006 Jul 05; 119(13):1108-12. PubMed ID: 16834930
    [No Abstract] [Full Text] [Related]

  • 8. Pathogenic and clinical aspects of Graves' disease.
    Feldt-Rasmussen U, Rasmussen AK, Zimmermann-Belsing T, Hartoft-Nielsen ML.
    Exp Clin Endocrinol Diabetes; 1999 Jul 05; 107 Suppl 3():S71-4. PubMed ID: 10522809
    [No Abstract] [Full Text] [Related]

  • 9. [Clinical and morphologic comparisons in toxic goiter].
    Grigor'ev PIa, Samoteĭkin MA, Korolev RV.
    Arkh Patol; 1967 Jul 05; 29(6):55-8. PubMed ID: 4178179
    [No Abstract] [Full Text] [Related]

  • 10. Graves' disease in childhood: advances in management with antithyroid drug therapy.
    Kaguelidou F, Carel JC, Léger J.
    Horm Res; 2009 Jul 05; 71(6):310-7. PubMed ID: 19506387
    [Abstract] [Full Text] [Related]

  • 11. [Graves-Basedow disease and pregnancy].
    Hanzlik J, Mardarowicz G.
    Pol Tyg Lek; 1976 Dec 27; 31(52):2239-41. PubMed ID: 63945
    [No Abstract] [Full Text] [Related]

  • 12. Clinical value of M22-based assays for TSH-receptor antibody (TRAb) in the follow-up of antithyroid drug treated Graves' disease: comparison with the second generation human TRAb assay.
    Massart C, Gibassier J, d'Herbomez M.
    Clin Chim Acta; 2009 Sep 27; 407(1-2):62-6. PubMed ID: 19576193
    [Abstract] [Full Text] [Related]

  • 13. [Evaluation of efficiency of the drug treatment of patients with toxic goiter].
    Zelinskiĭ BA, Slobodnianik OA.
    Vrach Delo; 1978 Apr 27; (4):115-8. PubMed ID: 78584
    [No Abstract] [Full Text] [Related]

  • 14. [Action of antithyroid drugs on the thyroid gland blood vessels in Basedow's disease].
    Yamasaki T.
    Yonago Acta Med; 1966 Jul 27; 10(2):69-73. PubMed ID: 4167195
    [No Abstract] [Full Text] [Related]

  • 15. Seizure during Graves' disease.
    Vergely N, Garnier P, Guy C, Khalfallah Y, Estour B.
    Epileptic Disord; 2009 Jun 27; 11(2):136-7. PubMed ID: 19269916
    [Abstract] [Full Text] [Related]

  • 16. Levels of autoantibodies against human TSH receptor predict relapse of hyperthyroidism in Graves' disease.
    Schott M, Morgenthaler NG, Fritzen R, Feldkamp J, Willenberg HS, Scherbaum WA, Seissler J.
    Horm Metab Res; 2004 Feb 27; 36(2):92-6. PubMed ID: 15002058
    [Abstract] [Full Text] [Related]

  • 17. [Criteria for recovery from diffuse toxic goiter].
    Baranov VG, Nikolaenko NF.
    Klin Med (Mosk); 1970 Apr 27; 48(4):50-3. PubMed ID: 4193305
    [No Abstract] [Full Text] [Related]

  • 18. Influence of short-term interruption of antithyroid drugs on the outcome of radioiodine therapy of Graves' disease: results of a prospective study.
    Eschmann SM, Thelen MH, Dittmann H, Bares R.
    Exp Clin Endocrinol Diabetes; 2006 May 27; 114(5):222-6. PubMed ID: 16804795
    [Abstract] [Full Text] [Related]

  • 19. [Does antithyroidal drug dose influence relapse of treated Graves-Basedow disease?].
    Jover Díaz F, Domínguez Escribano JR.
    An Med Interna; 2004 May 27; 21(5):259-60. PubMed ID: 15176936
    [No Abstract] [Full Text] [Related]

  • 20. Graves' disease.
    Rotondi M, Fonte R, Chiovato L.
    N Engl J Med; 2008 Sep 25; 359(13):1407-8; author reply 1409. PubMed ID: 18822458
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.